Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 6/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.52 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 6/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13907278 | 0.89 | CYP2A6 (0.62) | CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6 | |
| SCHEMBL3796332 | 0.85 | CYP2A6 (0.67) | CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6 | |
| SCHEMBL31673222 | 0.83 | GRM5 (0.64) | CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6 | |
| SCHEMBL401836 | 0.83 | GRM5 (0.64) | CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6 | |
| SCHEMBL28271722 | 0.82 | GPR55 (0.49) | CYP2C9CYP2C19CYP2D6CYP3A4FFAR1 | |
| SCHEMBL31673242 | 0.81 | CYP2A6 (0.58) | CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6 | |
| SCHEMBL16363849 | 0.81 | CYP2A6 (0.50) | CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6 | |
| SCHEMBL13730647 | 0.81 | GRM5 (0.50) | CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6 | |
| SCHEMBL4750576 | 0.80 | CYP2A6 (0.53) | CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6 | |
| SCHEMBL3837868 | 0.80 | CYP2A6 (0.53) | CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106854205-B | Inhibitors of influenza virus replication and methods of use and uses thereof | 广东东阳光药业有限公司 | 2019-07-09 | — | — | CN | disclosed |
| CN-109748915-A | Inhibitors of influenza viruses replication and its application method and purposes | 广东东阳光药业有限公司 | 2019-05-14 | — | — | CN | disclosed |
| US-7915424-B2 | Analgesics; anxiolytic agents | ELI LILLY AND COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1729771-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-10-14 | — | — | EP | disclosed |
| US-20080194647-A1 | Pyridyl Derivatives and Their Use as Mglu5 Antagonists | ELI LILLY AND COMPANY (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1729771-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094822-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194647-A1 | Pyridyl Derivatives and Their Use as Mglu5 Antagonists | HRH4, CNR2, CNR1 | CYP2A6 1624/4885CYP2C9 1673/4885CYP2B6 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.